TrialClinical pharmacology and therapeutics2022

Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.

Atoosa Rabiee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.